The Axios/Ipsos poll shows 20 percent of Americans now say they are either “not very likely” or “not at all likely” to get the vaccine, and 14 percent have effectively ruled it out. Both represent the lowest numbers recorded.
The numbers aren’t hugely different from where they have been in recent weeks, but overall the trend line is moving steadily downward. Through the first four months of the year, the number of skeptics had stayed mostly in the 30 percent range.
Those saying they are “not at all likely” has also dropped, from around 25 percent in late 2020 to 14 percent today.
The findings mirror those of other recent polls conducted before the FDA announcement that show a decline in vaccine hesitancy, though not a huge one. An NBC News poll last week showed the number of people saying they won’t get vaccinated or will do so only if required at 16 percent. The number was at 27 percent in October and 19 percent in April.
The Kaiser Family Foundation tracking poll last month showed more resilience in the most dug-in vaccine skeptics, with 17 percent saying they either won’t get vaccinated or will only do so if required. That’s similar to where that number has been throughout 2021.
But that poll also offers a middle-ground, “wait and see” option, and that group has steadily embraced the vaccine. In January, about half of those surveyed said they would either “wait and see” or not get vaccinated if they could choose; that number is down to 27 percent.
Perhaps the more interesting finding in the Axios/Ipsos poll involves a big emerging issue in the vaccination campaign: vaccinating children.
Polls have regularly shown parents are less sold on vaccinating their children than they are on vaccinating themselves, but the new poll shows a sharp decline in skepticism on vaccinating kids.
Since polling on this question began in May, at least 40 percent of parents have said they were unlikely to vaccinate their children as soon as it became possible, but that number dropped to 31 percent in the new poll.
The vaccines are approved for emergency use in children ages 12 to 17. But the FDA has moved to further study the vaccine’s effects on children ages 5 to 11, meaning it might not be available to them until early 2022. Some are growing impatient with that process as children return to school and prove significantly more susceptible to being infected by the delta variant.
The overall numbers suggest the FDA’s announcement hasn’t had an immediate, large impact on vaccine hesitancy in adults. And it’s quite possible the larger decline in hesitancy toward vaccinating children is more about the increasing threat the delta variant poses to them. But there has been a significant uptick in vaccinations in recent weeks, and these data suggest that’s in part because the skeptics are declining in number — albeit perhaps not as quickly as health officials would prefer.
The poll also suggests whatever further impact the FDA’s decision might have, it’s likely to be small. It shows about 8 percent of Americans are unvaccinated but say they are likely to get vaccinated. When asked about their intentions in light of the FDA fully approving the vaccine, that number ticked up slightly, to 10 percent.
In sum, the data reinforce that the larger impact of the FDA’s decision is likely to be in allowing employers and others to mandate vaccines. But the number of vaccine resisters they’ll confront is clearly declining.